NEW DELHI: Bharat Biotech (Krishna Ella, Chairman and Managing director) on Monday said it had begun human trials of Influenza A HINI (swine flu) vaccine to test its efficacy and safety after getting the nod of the national health regulator.
“Bharat Biotech is the first company in India to develop a cell culture based vaccine candidate for influenza, which can serve as a platform technology for both pandemic and seasonal flu vaccines,” the company said in a statement.
The Hyderabad based company said it had initiated the first phase of clinical trial in Bangalore with more than 150 volunteers for evaluating the safety and immunogenicity after getting the go ahead from the Drug Controller General of India (DCGI).
Bharat Biotech has earmarked a budget of Rs 70 crores for the development of the vaccine.
“The company expects to complete the trial in six weeks,” Bharat Biotech International Chairman and Managing Director, Mr Krishna Ella said.
Vaccines are one of the most effective ways to protect people from contracting illness during influenza epidemics and pandemics, Mr Ella said.